Three of the Best Biotech Penny Stocks to Buy Now

For investors looking for the best penny stocks to buy, the biotech sector offers some of the best investment opportunities on the market.

Despite the fact that biotech stocks have been up and down in 2014, Money Morning's Bioscience Investment Specialist Ernie Tremblay sees great profit opportunities for the rest of 2014.
penny stocks to buy "The Nasdaq Biotechnology Index (NBI) gained 20% in January/February 2014, then plunged 24% over the next six weeks, only to regain 16% by early this month," Tremblay said. "So what's going on? The market breathes in, and the market breathes out. After an overall gain of 130% over the past three years, an adjustment should come as no surprise to anyone. But that's all it is. There's no bursting bubble."
In fact, Tremblay believes that strong growth in prescription drug sales, growth in FDA drug approvals, increasing orphan drug development, and an aging U.S. population are all reasons to invest in biotech stocks now.

Now, penny stock investing is always risky. Penny stocks have the ability to bring massive profits in a short period of time, but they can also crash quickly. That's why Money Morning experts agree that penny stocks should only represent a small percentage of your investing capital - and you should do your research before buying.

That strategy still allows investors to profit from huge penny stock gains, while also minimizing risk.

That said - here are three of the best penny stocks in biotech to buy now...

Three Best Biotech Penny Stocks to Buy Now

Biotech Penny Stocks to Buy No. 1: Neuralstem Inc. (NYSE: CUR) produces neural stem cells of the human brain and spinal cord in commercial quantities.

At the end of July, Neuralstem completed phase 2 clinical trials of its ALS treatment NSI-566. The company also completed phase 1 trials for a chronic spinal cord injury treatment earlier this summer.

According toTremblay, passing FDA clinical trials is very difficult and investing in these companies facing trials can be very risky. However, passing those trials can bring huge profits to the company and its investors.

"A drug that succeeds in treating complex, treatment-resistant diseases would be a huge win not only for patients, but for investors as well," Tremblay said. "And when the market smells a whiff of success in the air, even during phased clinical studies, the prices often go wild."

CUR stock trades at $3.72, a 31% increase from the start of August. The penny stock has a 52-week range of $2.02 to $4.81.

Any additional news about CUR's clinical trials, could send the stock soaring in the coming months.

Money Morning Members, keep reading for two more of the best biotech penny stocks to buy now...

Biotech Penny Stocks to Buy No. 2: Oncothyreon Inc. (Nasdaq: ONTY) is a clinical-stage biopharmaceutical company that develops treatments for various types of cancer. Its lead product candidate, Stimuvax, is a cancer vaccine in phase 3 trials for non-small cell lung cancer. But the company also has a pipeline of numerous small-molecule product candidates.

ONTY is not profitable yet, but in the last quarter the company did post an earnings surprise of 30.8% when it reported an earnings per share (EPS) loss of $0.09 compared to estimates of a $0.13 loss. That was also better than the $0.14 loss the company posted the previous quarter.

Shares of ONTY are up more than 24% year to date, and currently trade at $2.18. Brokers surveyed by Thomson/First Call have an average price target of $3.50 set for ONTY, which would be a 61% from today's value.

Biotech Penny Stocks to Buy No. 3: Novavax Inc. (Nasdaq: NVAX) is a specialty biopharmaceutical company focused on finding treatments for infectious diseases. Its biggest product candidates include treatments for seasonal and pandemic influenza viruses, respiratory syncytial virus, and rabies.

In the September quarter, analysts expect NVAX to report revenue growth of nearly 102% compared to last year. For the full-year 2014, revenue growth is estimated at more than 72%. In August, analysts at Citigroup Inc. (NYSE: C) initiated a "Buy" rating on NVAX shares.

NVAX stock currently trades at $4.84, which is up 25% from the middle of April. Analysts polled by Thomson/First Call expect NVAX to head much higher however, and have an average price target of $10 on the stock. That would be an increase of 107% from today's price.

Join the conversation on Twitter @moneymorning and @KyleAndersonMM using #Penny Stocks

NOW: There's a simple investing strategy that lets institutional investors do all the heavy lifting, while the everyday traders - like us - take bigger gains...